Patents Examined by Lora M. Green
  • Patent number: 6078782
    Abstract: The invention relates to methods of performing a binding assay for an analyte of interest present in a sample based upon electrochemiluminescence at an electrode of interest. Particles are employed in the method, which are then collected in a zone at which electrochemiluminescence can be induced, wherein the amount of induced electrochemiluminescence is related to the amount of analyte in the sample.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 20, 2000
    Assignee: IGEN International Inc.
    Inventors: John K. Leland, Haresh P. Shah, John H. Kenten, Jack E. Goodman, George E. Lowke, Yuzaburo Namba, Gary F. Blackburn, Richard J. Massey
  • Patent number: 6017719
    Abstract: The invention provides a nonenzymic method for the release of cells which have been selected from a heterogeneous cell suspension by antibody-mediated binding to beads or other solid support. The method entails forming within the cell suspension a complex comprising the solid support linked to a primary monoclonal antibody, which in turn is bound to a cell surface antigen on the target cells. The complex is separated from the cell suspension, and then contacted with a specific peptide which binds to the primary antibody, displacing the antibody from the cell surface antigen, thereby releasing the target cell from the complex. The invention also provides methods for positive/negative cell selection wherein target cells having a first antigen are selected from a heterogeneous cell suspension containing undesired cells having a second antigen.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 25, 2000
    Assignee: Nexell Therapeutics, Inc.
    Inventors: Janet Tseng-Law, Joan A. Kobori, Fahad A. Al-Abdaly, Roy Guillermo, Sam L. Helgerson, Robert J. Deans
  • Patent number: 6013531
    Abstract: This invention provides a novel process of using magnetically responsive fluorescent polymer particles comprising polymeric core particles coated evenly with a layer of polymer containing magnetically responsive metal oxide as highly sensitive quantitative reagents for biochemical and immunological studies, wherein the fluorescent magnetic particles can serve as a marker for the number of particles. A wide variety of polymeric particles with sizes ranging from 1 to 100 microns can be used a core particles and transformed into magnetically responsive polymer particles. The surface of these magnetically responsive polymer particles can be coated further with another layer of functionalized polymer.
    Type: Grant
    Filed: August 22, 1995
    Date of Patent: January 11, 2000
    Assignee: Dade International Inc.
    Inventors: Chaeo-Huej J. Wang, Dinesh O. Shah
  • Patent number: 5989827
    Abstract: The present invention provides a process of designing compounds which bind to a specific target molecule. The process includes the steps of a) identifying a first ligand to the target molecule using two-dimensional .sup.15 N/.sup.1 H NMR correlation spectroscopy; b) identifying a second ligand to the target molecule using two-dimensional .sup.15 N/.sup.1 H NMR correlation spectroscopy; c) forming a ternary complex by binding the first and second ligands to the target molecule; d) determining the three dimensional structure of the ternary complex and thus the spatial orientation of the first and second ligands on the target molecule; and e) linking the first and second ligands to form the drug, wherein the spatial orientation of step (d) is maintained.
    Type: Grant
    Filed: October 31, 1996
    Date of Patent: November 23, 1999
    Assignee: Abbott Laboratories
    Inventors: Stephen W. Fesik, Philip J. Hajduk, Edward T. Olejniczak
  • Patent number: 5968736
    Abstract: Encoded combinatorial chemistry is provided, where sequential synthetic schemes are recorded using organic molecules, which define choice of reactant, and stage, as the same or different bit of information. Various products can be produced in the multi-stage synthesis, such as oligomers and synthetic non-repetitive organic molecules. Conveniently, nested families of compounds can be employed as identifiers, where number and/or position of a substituent define the choice. Alternatively, detectable functionalities may be employed, such as radioisotopes, fluorescers, halogens, and the like, where presence and ratios of two different groups can be used to define stage or choice. Particularly, pluralities of identifiers may be used to provide a binary or higher code, so as to define a plurality of choices with only a few detachable tags. The particles may be screened for a characteristic of interest, particularly binding affinity, where the products may be detached from the particle or retained on the particle.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 19, 1999
    Assignees: Cold Spring Harbor Laboratory, Trustees of Columbia University in the City of New York
    Inventors: W. Clark Still, Michael H. Wigler, Michael H. J. Ohlmeyer, Lawrence W. Dillard, John C. Reader
  • Patent number: 5968753
    Abstract: The invention provides a non-enzymatic method for the release of cells which have been positively selected from a heterogeneous cell suspension by antibody-mediated binding to beads or other solid support. The method entails forming within the cell suspension a complex comprising the solid support linked to a primary antibody, which in turn is specifically bound to a cell surface antigen on the target cells. The complex is separated from the cell suspension, and then contacted with a specific peptide which binds to the primary antibody, displacing the antibody from the cell surface antigen, thereby releasing the target cell from the complex. The invention also provides methods for positive/negative cell selection wherein target cells having a first antigen are selected from a heterogeneous cell suspension containing undesired cells having a second antigen.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 19, 1999
    Assignee: Nexell Therapeutics, Inc.
    Inventors: Janet Tseng-Law, Joan A. Kobori, Fahad A. Al-Abdaly, Roy Guillermo, Sam L. Helgerson, Robert J. Deans
  • Patent number: 5965106
    Abstract: A method for in-vivo targeting a functional moiety in a patient by administering a targeting moiety coupled to an affinity component, wherein the targeting moiety has affinity for binding sites in a target area, and administering a binding partner to the affinity component coupled to a functional moiety to localize the functional moiety in the target area. Preferably the targeting moiety is an antibody and the functional moiety is a radiometal when performing in vivo imaging or therapy. The affinity component may be a novel methotrexate analog. Preferably, the affinity component is thermo-stabilized.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: October 12, 1999
    Assignee: PerImmune Holdings, Inc.
    Inventors: Nicholas Pomato, Richard P. McCabe, Gregory A. Hawkins, Reinhard Bredehorst, Chong-Ho Kim, Carl-Wilhelm Vogel
  • Patent number: 5962218
    Abstract: The invention relates to methods, apparatus, reagents, and kits for performing a binding assay for an analyte of interest present in a sample based upon electrochemiluminescence at an electrode of interest. In the method, reagents and kits particles can be employed; for instance, for settling upon the electrode surface by gravity, centrifugation or magnetic attraction. The apparatus can include a magnet for generating a magnetic field in a region proximate the electrode.
    Type: Grant
    Filed: November 24, 1993
    Date of Patent: October 5, 1999
    Assignee: IGEN International Inc.
    Inventors: Jonathan K. Leland, Haresh P. Shah, John H. Kenten, Jack E. Goodman, George E. Lowke, Gary F. Blackburn, Richard J. Massey
  • Patent number: 5935779
    Abstract: The invention relates to methods of performing a binding assay for an analyte of interest present in a sample based upon electrochemiluminescence at an electrode of interest. Particles are employed in the method, which are then collected in a zone at which electrochemiluminescence can be induced, wherein the amount of induced electrochemilurninescence is related to the amount of analyte in the sample.
    Type: Grant
    Filed: November 30, 1994
    Date of Patent: August 10, 1999
    Assignee: IGEN International Inc.
    Inventors: Richard J. Massey, Jonathan K. Leland, Haresh P. Shah, John H. Kenten, Jack E. Goodman, George E. Lowke, Yuzaburo Namba, Gary F. Blackburn
  • Patent number: 5919645
    Abstract: A method for the direct determination of the toxicity of a solid material by direct contact between the solid sample and a luminescent microorganism, consisting of the steps of forming a suspension of a luminescent microorganism in a 0.5% to 6% solution of NaCl or 20% solution of sucrose in distilled water diluent and contacting a sample of the solid to be tested directly with the suspension of luminescent microorganisms. A control including the microorganism in the diluent is also prepared. The combination of microorganism suspension and solid sample is incubated for a sufficient time to allow for the toxicity of the sample to affect the metabolism of the living organism. During or subsequent to the incubation period the combined organism and sample are subjected to a separation step to separate a major portion of the particulate solid from the suspension of microorganisms.
    Type: Grant
    Filed: April 9, 1991
    Date of Patent: July 6, 1999
    Assignee: Azur Environmental
    Inventors: Ker-Kong Tung, Charles Walbourn, Grace Scheibner
  • Patent number: 5891643
    Abstract: The present invention provides a process of designing compounds which bind to a specific target molecule. The process includes the steps of a) identifying a first ligand to the target molecule using two-dimensional .sup.15 N/.sup.1 H NMR correlation spectroscopy; b) identifying a second ligand to the target molecule using two-dimensional .sup.15 N/.sup.1 H NMR correlation spectroscopy; c) forming a ternary complex by binding the first and second ligands to the target molecule; d) determining the three dimensional structure of the ternary complex and thus the spatial orientation of the first and second ligands on the target molecule; and e) linking the first and second ligands to form the drug, wherein the spatial orientation of step (d) is maintained.
    Type: Grant
    Filed: November 14, 1995
    Date of Patent: April 6, 1999
    Assignee: Abbott Laboratories
    Inventors: Stephen W. Fesik, Philip J. Hajduk, Edward T. Olejniczak
  • Patent number: 5885842
    Abstract: Non-invasive methods have been developed for the measurement of NO levels in a variety of fluid media, e.g., body fluids. The present invention embraces the use of a semi-permeable vessel wherein said vessel contains an NO reacting substance to trap NO diffusing thereinto, and a simple physical or chemical detection method to measure the levels of the end products. Since NO is a neutral gas molecule, it is capable of diffusing freely across a wide range of biocompatible polymer membranes which exhibit a high permeability to NO and other neutral gas molecules, such as O.sub.2 and CO.sub.2, but which are not permeable to charged molecules, such as NO.sub.3.sup.- or NO.sub.2.sup.-. The latter two compounds are ubiquitously present in body fluids and often interfere with the measurement of NO levels. The permeability of selected membranes to NO, but not to NO.sub.3.sup.- or NO.sub.2.sup.
    Type: Grant
    Filed: November 8, 1996
    Date of Patent: March 23, 1999
    Assignee: Medinox, Inc.
    Inventor: Ching-San Lai
  • Patent number: 5879656
    Abstract: Conjugated compounds which comprises an ST receptor binding moiety and a radiostable active moiety are disclosed. Pharmaceutical compositions comprising a pharmaceutically acceptable carrier or diluent, and a conjugated compound which comprises an ST receptor binding moiety and a radiostable active moiety or an ST receptor binding moiety and a radioactive active moiety are disclosed. Methods of treating an individual suspected of suffering from metastasized colorectal cancer comprising the steps of administering to said individual a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent, and a therapeutically effective amount of a conjugated compound which comprises an ST receptor binding moiety and a radiostable active moiety or an ST receptor binding moiety and a radiostable active moiety are disclosed.
    Type: Grant
    Filed: January 5, 1996
    Date of Patent: March 9, 1999
    Assignee: Thomas Jefferson University
    Inventor: Scott A. Waldman
  • Patent number: 5872124
    Abstract: The process of treating a disease of the central nervous system with an agent from one or more of the following three classes of agents: (1) nitric oxide scavengers, (2) peroxynitrite scavengers, and (3) agents that either interfere with the synthesis of iNOS in the cell or the enzymatic activity of iNOS in the cell.
    Type: Grant
    Filed: July 31, 1996
    Date of Patent: February 16, 1999
    Assignee: Thomas Jefferson University
    Inventors: Hilary Koprowski, Douglas Craig Hooper, John L. Farber
  • Patent number: 5869622
    Abstract: The present invention relates to the PUR protein, nucleotide sequences and expression vectors encoding PUR, and to methods for inhibiting PUR activity. More specifically, the invention relates to polyclonal and monoclonal antibodies that bind PUR or PUR related proteins. Antibodies that bind PUR protein and which neutralize. PUR activity may be used to treat hyperproliferative diseases such as cancer.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 9, 1999
    Assignee: Mount Sinai School of Medicine of the City University of New York
    Inventors: Edward M. Johnson, Andrew D. Bergemann
  • Patent number: 5866335
    Abstract: The synthesis of 10,10'-substituted-9,9'-biacridine molecules and their derivatives is disclosed. These molecules are shown to catalyze the production of light by chemiluminescence in the presence of a signal solution having at a pH from about 10.0 to about 14.0, at a concentration effective for producing a chemiluminescent signal, a chelating agent, a sulfoxide, a reducing sugar, an oxidant or combination of oxidants, an alcohol and aqueous sodium tetraborate. These 10,10'-substituted-9,9'-biacridines are used alone or attached to haptens or macromolecules and are utilized as labels in the preparation of chemiluminescent, homogeneous or heterogeneous assays. They are also used in conjunction with other chemiluminescent label molecules to produce multiple analyte chemiluminescent assays.
    Type: Grant
    Filed: December 16, 1996
    Date of Patent: February 2, 1999
    Assignee: George W. Katsilometes
    Inventors: George W. Katsilometes, Pak T. Ho
  • Patent number: 5866343
    Abstract: A `docking` method based on finite grid forcefield sampling makes use of fast evaluation of interaction energies between molecules, such as macromolecules and ligands. The forcefield used to calculate interaction energies utilizes a potential energy function composed of a 1/r dependent electrostatic term and a (6-12) Lennard-Jones term for Van der Waals interactions. Successful prediction of ligand position and determination of ligand-protein interaction enthalpy is done by mapping potential energy field components of one of the molecules onto a energy field component grids, and mapping interaction field components of another of the two molecules onto interaction component grids.
    Type: Grant
    Filed: April 15, 1997
    Date of Patent: February 2, 1999
    Assignee: Universite de Montreal
    Inventors: Nico Blom, Jurgen Sygusch
  • Patent number: 5866322
    Abstract: The present invention includes novel rubella assays employing a Rubella virus capture reagent and a solid phase material containing a reaction site comprising a polymeric cation substance. A test sample suspected of containing Rubella antibody may be contacted with the capture reagent to form a capture reagent/analyte complex. The complex is then contacted to the positively charged solid phase to attract, attach, and immobilize the capture reagent/analyte complex.
    Type: Grant
    Filed: October 11, 1991
    Date of Patent: February 2, 1999
    Assignee: Abbott Laboratories
    Inventors: Yi-Her Jou, Stephen D. Stroupe, Janina Adamczyk, John Safford
  • Patent number: 5866342
    Abstract: The invention provides systems and methods for synthesizing various compounds on solid support. According to one exemplary method, a synthesizer is provided having at least one reaction vessel block with a plurality of reaction vessels therein. At least one solid support is introduced into a least some of the reaction vessels, and a reagent is introduced into the reaction vessels having the solid supports. The reaction vessel block is then vibrated while heat is supplied to the reaction vessel block to heat the reaction vessels. Optionally, the synthesized compounds may be cleaved from the solid supports following synthesis while they remain within the reaction vessels.
    Type: Grant
    Filed: September 27, 1996
    Date of Patent: February 2, 1999
    Assignee: Glaxo Group Limited
    Inventors: Valery V. Antonenko, Nicolay Kulikov
  • Patent number: 5866344
    Abstract: The invention relates to novel competitive immunoassays that are useful in detecting and quantitatively measuring analytes down to the nanomolar range. The invention also includes methods of selecting antibodies from libraries of polypeptides expressed on a cell surface. In conducting immunoassays, anti-analyte antibody molecules are expressed on the surface of a bacterial cell and then used to bind with labeled analyte. Quantitation is performed by competitively displacing the bound labeled analyte with a known amount of analyte and measuring the label. The method is rapid and inexpensive and may be performed with readily available safe labeling reagents such as fluorescent compounds.
    Type: Grant
    Filed: May 23, 1995
    Date of Patent: February 2, 1999
    Assignee: Board of Regents, The University of Texas System
    Inventor: George Georgiou